Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Regeneron, CytomX announce bispecific therapeutics for cancer collab

Regeneron, CytomX announce bispecific therapeutics for cancer collab

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. have announced a strategic research collaboration within the field of conditionally activated bispecific therapeutics for the treatment of cancer.

Using CytomX’s Probody and Regeneron’s Veloci-Bi platforms, the collaboration and licensing agreement aims to enable the development of investigational next-generation bispecific immunotherapies.

Strategically focused on applying Probody’s biologic masking strategies for developing Regeneron’s investigational bispecifics – which remain inactive until activated by proteases in the tumour microenvironment – the technology seeks to widen the therapeutics window. It will also help minimise off-target effects for these next-generation T-cell engaging therapies and potentially address tumour types historically unresponsive to immunotherapy.

Dr John Lin, senior vice president of immune-oncology and head of bispecifics at Regeneron, said: “The collaboration will enable Regeneron and CytomX to combine our collective oncology expertise with two premier platforms […] to develop novel immunotherapies and research their potential to transform patient lives.”

CEO and chairman of CytomX, Sean McCarthy, PhD, said: “We are thrilled that our scientific expertise has attracted Regeneron as our newest collaborator, and we look forward to working closely together to further optimise T-cell engager strategies and push the boundaries of cancer immunotherapy to new levels.”

Physician-scientist led biotech Regeneron will be responsible for funding preclinical and clinical development and commercialisation activities, while oncology-focused biopharma CytomX will receive $30 million in an upfront payment, with the potential for up to $2 billion in research, development, regulatory, and sales-based milestones, also.

CytomX’s pipeline currently comprises seven therapeutic candidates across multiple treatment modalities, including antibody-drug conjugates (ADCs), T-cell engaging bispecific antibodies (TCBs), and immune modulators such as cytokines and checkpoint inhibitors (CPIs). Its CW-2029 – developed in collaboration with AbbVie – is an investigational, conditionally activated ADC directed towards CD71 and has demonstrated encouraging anti-tumour activity in patients with squamous non-small cell lung cancer (NSCLC).

Meanwhile, its clinical pipeline also includes CTLA-4-targeting Probody therapeutics BMS-986249 and BMS-986288 – developed in partnership with Bristol Myers Squibb – and CX-904, a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumour cells and the CD3 receptor on T-cells, developed in partnership with Amgen.

The deal with Regeneron comes months after CytomX Therapeutics laid off 40% of its workers.

November 21, 2022


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote